Recent 8-K filings for CTOR

• June 1, 2026, 4:30 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

  24% ORR (5 partial responses) among 21 efficacy-evaluable patients with recurrent/refractory gynecologic malignancies.

• May 15, 2026, 4:44 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Citius Oncology reports Q2 FY2026 net loss $26.6M; LYMPHIR revenue $1.7M, launch progressing

  Net product revenues $1.7M in Q2 ($5.6M H1) vs $0 prior year; gross margin 80%.

• May 6, 2026, 7:59 PM ET debt materiality 0.75 positive item 1.01item 2.03item 3.02item 8.01item 9.01 ◈ Material Agreements

  Citius Oncology secures up to $36.5M in debt and warrant exercise proceeds

  Warrant inducement yields ~$11.5M gross from exercise of 12.8M shares at $0.90; new warrants for 25.6M shares at $0.90.

• April 28, 2026, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

  Citius Oncology receives Nasdaq deficiency notice for falling below $1.00 bid price

  Nasdaq notified Citius Oncology on April 22, 2026 that bid price closed below $1.00 for 30 consecutive business days.

• March 31, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Citius Oncology reports early LYMPHIR launch traction; 83% of target accounts in formulary review

  83% of target accounts have added or are actively progressing LYMPHIR through formulary review.

• March 10, 2026, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Citius Oncology reports positive Phase 1 topline data for LYMPHIR + pembrolizumab in gynecologic cancers

  24% objective response rate (ORR) and 48% clinical benefit rate (CBR) among 21 evaluable patients.

• March 4, 2026, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Citius Oncology reports positive Phase 1 data for LYMPHIR prior to CAR-T in DLBCL

  Overall response rate 86% (57% complete response, 29% partial response) at one month in 14 patients.

• February 13, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Citius Oncology reports first revenue of $3.9M from LYMPHIR launch; net loss narrows to $5.5M

  Revenue of $3.9M for Q1 FY2026 ended Dec 31, 2025, first reported sales following December 2025 commercial launch of LYMPHIR.

• December 23, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Citius Oncology reports FY 2025 net loss of $24.8M; launches LYMPHIR in U.S.

  Net loss of $24.8M ($0.34 per share) vs $21.1M ($0.31) in FY 2024, driven by pre-commercial investment.

• December 10, 2025, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01

  Citius Oncology raises $18M in registered direct & private placement; funds LYMPHIR launch

  Gross proceeds ~$18M from sale of 1,284,404 shares at $1.09 + 15,229,358 pre-funded warrants at $1.0899 per unit.

• December 1, 2025, 6:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Citius Oncology launches LYMPHIR, first commercial product, for CTCL

  LYMPHIR (denileukin diftitox-cxdl) now available nationwide via specialty distributors.

• October 23, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Citius Oncology corporate presentation confirms LYMPHIR launch in Q4 2025; $400M+ market

  LYMPHIR (denileukin diftitox) FDA-approved Aug 2024 for relapsed/refractory CTCL; first new systemic therapy since 2018.

• September 19, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.02item 5.02item 9.01

  Citius Oncology doubles share reserve to 30M under 2024 equity plan; issues 360K warrants

  Board approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.

• September 10, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01

  Citius Oncology raises $9.0M in registered direct offering and warrant private placement

  Sold 5,142,858 shares and warrants for 5,142,858 shares at $1.75/unit for gross proceeds of $9.0M.

• August 12, 2025, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Citius Oncology reports Q3 net loss $5.4M; LYMPHIR launch on track for Q4 2025

  Net loss of $5.4M ($0.08/share) for fiscal Q3 ended June 30, 2025, vs $4.8M ($0.07) a year ago.

• July 18, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Citius Oncology closes $9.0M public offering of 6.82M shares & warrants

  Priced 6,818,182 units at $1.32 each, each consisting of 1 share + 1 warrant for 1 common share.

• June 27, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01

  Citius Oncology regains Nasdaq minimum bid price compliance

  Received Nasdaq compliance notice on June 26, 2025, for Listing Rule 5550(a)(2).

• June 17, 2025, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Citius Oncology nearing commercial launch of LYMPHIR for CTCL in H2 2025

  Commercial-scale manufacturing completed; inventory sufficient for 12-18 months post-launch with 60-month shelf life.

• May 14, 2025, 7:59 PM ET earnings materiality 0.90 negative item 2.02item 9.01

  Citius Oncology Q2 net loss widens to $7.7M; cash only $112, needs funding beyond May 2025

  Net loss of $7.7M ($0.11 per share) vs $4.8M loss a year ago; R&D and G&A expenses increased due to launch activities.

• April 25, 2025, 7:59 PM ET other material materiality 0.75 negative item 3.01

  Citius Oncology receives Nasdaq deficiency notice for bid price below $1.00

  Nasdaq notified Citius Oncology that its common stock bid price closed below $1.00 for 30 consecutive business days.

• April 3, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01item 9.01

  Citius Oncology restructures $14.1M payment obligation to Eisai for LYMPHIR milestone and development costs

  Total owed: $5.9M milestone payment plus $8.23M in development and inventory costs.

• February 14, 2025, 6:59 PM ET earnings materiality 0.75 negative item 8.01item 2.02item 9.01

  Citius Oncology reports wider Q1 net loss of $6.7M; engaged Jefferies for strategic alternatives

  Net loss of $6.7M ($0.09/share) vs $4.7M ($0.07) in Q1 fiscal 2024.

• February 6, 2025, 6:59 PM ET regulatory materiality 0.60 positive item 8.01item 9.01

  LYMPHIR assigned permanent J-code J9161 by CMS, effective April 1, 2025

  LYMPHIR (denileukin diftitox-cxdl) received permanent HCPCS J-code J9161 for IV use, 1 microgram.

• January 7, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Citius Oncology provides LYMPHIR launch update; commercialization planned for H1 2025

  LYMPHIR (immunotherapy for CTCL) approved Aug 2024; launch targeted for first half of 2025.

• December 27, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Citius Oncology full-year net loss widens to $21.1M; FDA-approved LYMPHIR launch on track for H1 2025

  Net loss $21.1M ($0.31/sh) vs $12.7M ($0.19/sh) for FY ended Sep 30, 2024.

• September 5, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Citius Oncology's LYMPHIR added to NCCN Guidelines (Category 2A) for CTCL

  LYMPHIR (denileukin diftitox-cxdl) included in NCCN Guidelines for relapsed/refractory Cutaneous T-cell Lymphoma as Category 2A recommendation.

• August 26, 2024, 7:59 PM ET other material materiality 0.80 negative item 2.01item 9.01

  SpinCo reports $14.3M net loss for nine months; going concern uncertainty raised

  Net loss of $14.3M for nine months ended June 30, 2024 (vs $7.5M prior year); no revenue.

• August 16, 2024, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 2.01item 5.06item 9.01item 5.02item 3.02item 3.03item 4.01item 5.01item 5.03 ◈ executive_change ×4

  Citius Oncology completes de-SPAC business combination; CTOR begins trading

  Citius Pharma received 65.6M shares (~92.6% ownership); 4.3M SPAC shares redeemed for ~$49.3M ($11.47 each).

• August 5, 2024, 7:59 PM ET other material materiality 0.85 neutral item 5.02item 5.07item 8.01item 9.01

  TenX Keane shareholders approve business combination with Citius Oncology; redemptions total $49.3M

  All eight proposals approved, including business combination, domestication to Delaware, name change to Citius Oncology, and 15M-share stock incentive plan.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

17 positive 5 negative 18 neutral

source · CTOR on sec.gov